AU2006332728A1 - Method of identifying compounds useful to treat neuronal degenerative diseases - Google Patents

Method of identifying compounds useful to treat neuronal degenerative diseases Download PDF

Info

Publication number
AU2006332728A1
AU2006332728A1 AU2006332728A AU2006332728A AU2006332728A1 AU 2006332728 A1 AU2006332728 A1 AU 2006332728A1 AU 2006332728 A AU2006332728 A AU 2006332728A AU 2006332728 A AU2006332728 A AU 2006332728A AU 2006332728 A1 AU2006332728 A1 AU 2006332728A1
Authority
AU
Australia
Prior art keywords
sod
gtpase
protein
isolated
rac1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006332728A
Other languages
English (en)
Inventor
John F. Engelhardt
Maged M. Harraz
Jennifer J. Marden
Weihong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation
Original Assignee
University of Iowa Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation filed Critical University of Iowa Research Foundation
Publication of AU2006332728A1 publication Critical patent/AU2006332728A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
AU2006332728A 2005-12-30 2006-12-28 Method of identifying compounds useful to treat neuronal degenerative diseases Abandoned AU2006332728A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75533705P 2005-12-30 2005-12-30
US60/755,337 2005-12-30
PCT/US2006/049424 WO2007079141A2 (en) 2005-12-30 2006-12-28 Method of identifying compounds useful to treat neuronal degenerative diseases

Publications (1)

Publication Number Publication Date
AU2006332728A1 true AU2006332728A1 (en) 2007-07-12

Family

ID=38134984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006332728A Abandoned AU2006332728A1 (en) 2005-12-30 2006-12-28 Method of identifying compounds useful to treat neuronal degenerative diseases

Country Status (6)

Country Link
US (3) US20070265350A1 (enExample)
EP (1) EP1971867A2 (enExample)
JP (1) JP2009521928A (enExample)
AU (1) AU2006332728A1 (enExample)
CA (1) CA2634670A1 (enExample)
WO (1) WO2007079141A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
EP1971867A2 (en) * 2005-12-30 2008-09-24 University of Iowa Research Foundation Method of identifying compounds useful to treat neuronal degenerative diseases
EP2970873A4 (en) * 2013-03-14 2017-02-22 President and Fellows of Harvard College Methods for selecting microbes from a genetically modified library to detect and optimize the production of metabolites
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (en) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
KR20200088856A (ko) * 2017-11-15 2020-07-23 벤더르빌트 유니버시티 리소좀 기능의 개선 및 퇴행성 신경 질환의 치료를 위한 방법 및 조성물
EP4724816A2 (en) * 2023-06-06 2026-04-15 Mclaughlin Research Institute for Biomedical Sciences Methods for detecting the presence of at least one misfolded form of sod1 in a biological sample

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083713A (en) * 1992-08-31 2000-07-04 Bristol-Myers Squibb Company Cloning and expression of βAPP-C100 receptor (C100-R)
US5939460A (en) * 1996-07-08 1999-08-17 Idun Pharmaceuticals, Inc. Method of inhibiting NADPH oxidase
IL128017A0 (en) * 1998-07-22 1999-11-30 Technion Res & Dev Foundation Method for detecting protein-protein interactions and a kit therefor
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.
EP1131425A2 (en) * 1998-11-18 2001-09-12 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
CA2270795A1 (en) 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
US6485950B1 (en) * 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
WO2003006614A2 (en) * 2001-07-12 2003-01-23 Exelixis, Inc. UBE2s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
JP2003201255A (ja) * 2001-11-05 2003-07-18 Otsuka Pharmaceut Factory Inc アルツハイマー病予防および治療剤
WO2003087399A1 (en) * 2002-04-17 2003-10-23 Glucox Ab Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
WO2004047772A2 (en) * 2002-11-26 2004-06-10 Florida Atlantic University Catalytic antioxidants and methods of use
KR100522188B1 (ko) 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
EP1602926A1 (en) * 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
EP1971867A2 (en) * 2005-12-30 2008-09-24 University of Iowa Research Foundation Method of identifying compounds useful to treat neuronal degenerative diseases

Also Published As

Publication number Publication date
US20090239243A1 (en) 2009-09-24
US20080206792A1 (en) 2008-08-28
WO2007079141A9 (en) 2007-08-30
JP2009521928A (ja) 2009-06-11
CA2634670A1 (en) 2007-07-12
WO2007079141A2 (en) 2007-07-12
EP1971867A2 (en) 2008-09-24
WO2007079141A3 (en) 2008-01-31
US20070265350A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
Zhang et al. Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation
US20090239243A1 (en) Method of identifying compounds useful to treat neuronal degenerative diseases
US10105420B2 (en) Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
S. Hernandes et al. NADPH oxidase and neurodegeneration
US20180338991A1 (en) Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
US20080261201A1 (en) Methods and compounds to alter virus infection
EP2039367B1 (en) Prophylactic/therapeutic agent for neurodegenerative disease
CN102282162B (zh) 用于增强dna修复的物质和组合物及使用方法
WO2005050170A2 (en) Methods and compositions for inhibiting intracellular aggregate formation
US9766241B2 (en) PGC-1beta-protein-function regulator, mitochondria-function regulator, anti-obesity agent, and screening method therefor
US20160031955A1 (en) Methods for Treating Mitochondrial Disorders and Neurodegenerative Disorders
US20130157959A1 (en) Use of hades as tumor suppressor target
KR101943706B1 (ko) 유비퀴틴 활성 저해용 조성물
KR100880850B1 (ko) 고형암 세포에서 사이클로필린 ａ의 발현을 억제하는물질을 포함하는 시스플라틴에 대한 내성 억제용 약제학적조성물 및 그를 이용하여 고형암의 시스플라틴에 대한내성을 억제하는 방법
KR100898866B1 (ko) 원 종양유전자 단백질 ｄｅｋ를 이용하여 세포사멸을유도하는 조성물 및 방법 및 ｄｅｋ를 발현하는 형질전환초파리
JAQUET " Identification of pharmacological inhibitors of NADPH oxidases for the treatment of oxidative stress-derived pathologies
Warr Regulation of LASU1-mediated Mcl-1 Degradation and its Roles in Apoptosis
JP2005281140A (ja) Ｓｃｃａによるｊｎｋ−１キナーゼ活性の抑制方法
KR20090081884A (ko) 백스 인히비터-1을 유효성분으로 포함하는 ｅｒ-스트레스매개 질환의 예방 및 치료용 조성물
US20100113557A1 (en) Method for prevention of tumor
CN112409459A (zh) 一种多肽及其在制备治疗乳腺癌药物中的应用
JP2005287418A (ja) 細胞殺傷性と細胞死防御性とを併せもつペプチド
Guinart Target Validation For Neurofibromatosis Type 2 Therapeutics.
Thomas MCL-1 is Essential for Myocardial Homeostasis and Autophagy
JP2007056008A (ja) ｍ−カルパインおよび／またはμ−カルパインによるＰＥＰ−１９の分解を阻害することを特徴とする虚血性脳疾患の治療方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application